PHARMERIT INTERNATIONAL: According to statistics provided by Cancer Research UK (CRUK), vulval cancer incidence rates have increased overall in Great Britain since the mid-1970s, due to increased prevalenc

Data-sharing agreement from NHS Digital registers of approved data releases, 2014–2019. Evidence status: source reported.

Organisation: PHARMERIT INTERNATIONAL
Source reference: DARS-NIC-28480-W2R8F-v1.4
Jurisdiction: England
Licence: Open Government Licence v3.0, subject to NHS England terms and exclusions

Register reference: DARS-NIC-28480-W2R8F-v1.4
Agreement period: not published to no end date published
For commercial purposes (as marked in the register): Not stated
Release files listed by NHS England: 18

Data approved

Hospital Episode Statistics Admitted Patient Care
Hospital Episode Statistics Outpatients

Objective, as published

According to statistics provided by Cancer Research UK (CRUK), vulval cancer incidence rates have increased overall in Great Britain since the mid-1970s, due to increased prevalence of human papillomavirus (HPV), other sexually transmitted infections, and smoking. Without appropriate preventative advice or other intervention, it is expected that rates will continue to rise. CRUK report that in 2011, there were 1,200 diagnoses of vulval cancer, and approximately 400 deaths in 2012, more than one every day. In the case of vaginal cancer there were 256 diagnoses in 2011 and 111 deaths (equating to around two per week) in 2012. Despite rising disease incidence rates, there are currently no published figures for the cost of a case of vaginal or vulval cancer, nor of their precursor lesions, vulval intraepithelial neoplasia (VIN) and vaginal intraepithelial neoplasia (VaIN), in the United Kingdom (UK). Pharmerit Ltd wish to process patient-level data to estimate the economic burden of vulval and vaginal cancers on the National Health Service (NHS), with the final aim of reporting their findings in the form of a manuscript for publication in a peer-reviewed journal. Outputs produced will only ever contain aggregate data with small numbers supressed in line with the HES analysis guide) will then be available sourced by other parties including health funding decision-makers and those who have an influence on decisions for use as inputs into cost-effectiveness analyses and other forec…

Expected benefits, as published

By calculating the cost to the NHS of vaginal and vulvar cancer as well as the precancerous lesions VIN and VaIN, this work will fill a gap in current knowledge. This information can be used in economic analyses of preventative measures, treatments and procedures related to these conditions. Fully-informed economic analyses ensure optimal use of a limited health budget, by maximising health gains, and thus improve the efficiency of the health and social care system as a whole. For the vaginal/vulvar cancer patient this would mean a more efficient care pathway and access to more effective treatments and procedures, which in turn would improve prognosis and increase patient quality of life. Such benefits would begin to be seen as soon as the information is in the public domain, as from this…

Source: https://webarchive.nationalarchives.gov.uk/ukgwa/2019/http://content.digital.nhs.uk/media/23167/Data-Release-Register-September---November-2016/xls/Data_Release_Register__September_-_November_2016.xlsx. Captured 2026-10-30.

Limitations: Agreement as recorded in an NHS Digital register of approved data releases (2014–2019), retrieved from the UK Government Web Archive. That register lists releases made in its period and the agreement's purpose statement as it then stood; it gives no agreement dates, and the agreement may have changed since. Imported only where a paper quotes a reference no current register holds.